Published 3 months ago • loading... • Updated 3 months ago

Phraxis Announces FDA Approval of EndoForce™ Connector for Endovascular Venous Anastomosis, Advancing Dialysis Access Innovation

On May 22, 2025, Phraxis Inc., a medical device company headquartered in Minneapolis, received FDA approval for its EndoForce Connector designed for endovascular venous anastomosis.
The approval follows a pivotal, multicenter, single-arm study that demonstrated EndoForce's ability to simplify arteriovenous graft creation while addressing vascular access challenges.
EndoForce is a patented implant designed to enable precise vessel-to-graft alignment without surgical venous dissection, aiming to reduce tissue trauma and improve procedural workflow.
The study achieved a 92% cumulative patency rate at six months and confirmed technical and primary patency success, with John Ross, MD, highlighting its novel, straightforward approach.
Phraxis has made EndoForce available to clinicians, signaling a potential advancement in durable dialysis access solutions for patients with end-stage renal disease.

Insights by Ground AI

Does this summary seem wrong?

19 Articles

Chippewa Herald

+18 Reposted by 18 other sources

Center

Phraxis Announces FDA Approval of EndoForce™ Connector for Endovascular Venous Anastomosis, Advancing Dialysis Access Innovation

MINNEAPOLIS, May 22, 2025 /PRNewswire/ -- Phraxis Inc., a Minneapolis-based medical device company, marks a major milestone with FDA approval of the EndoForce™ Connector for Endovascular Venous Anastomosis (EndoForce™) — a pivotal development in the evolution of dialysis access technology.

3 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year